

June 13, 2024

Perseus Proteomics, Inc.

President & CEO: Takuya Yokokawa

e-mail: ir@ppmx.com

PPMX-T004 Joint Research Results Presented at 2024 Annual Congress of the European Association for Cancer Research (EACR 2024)

Perseus Proteomics Inc. ("the Company") is pleased to announce that the results of the joint research on antibody drug conjugate (ADC) by UBE Corporation (HQ: Minato-ku, Tokyo; President & Representative Director: Masato Izumihara) and the Company were selected and presented at the EACR 2024 Congress.

Date: June 12, 2024 (CET; EACR: June 10 – 13, 2024)

Title : Preclinical evaluation of a novel antibody-drug conjugate (ADC) targeting CDH3

Author: S. Hagiwara^{*}, H. Akiyoshi^{*}, S. Kaneko^{*}, S. Nonouchi^{**}, R. Iwamura^{**},
T. Kashiwagi^{**}, G. Mizuno^{**}, Y. Wada^{**}, T. Matsushita^{**}, M. Hikichi^{*},
Y. Aikawa^{*}

(*Perseus Proteomics Inc, **UBE Corporation)

Place: Rotterdam, the Netherlands

■ About Perseus Proteomics

Perseus Proteomics is a biotech venture established in February 2001, aiming to develop novel antibody therapeutic drugs mainly for cancer. The Company has been developing PPMX-T002, an RI labelled antibody, PPMX-T004, an antibody drug conjugate (ADC), and PPMX-T003, a first-in-class transferrin receptor 1 blocking antibody. Currently, investigator-led phase I/II clinical trial of PPMX-T003 among aggressive NK-cell leukemia (ANKL) patients and phase I clinical trial among polycythemia vera patients are also underway.

<https://www.ppmx.com/en/>

END